Motilal Oswal starts Molbio Diagnostics with Buy, ₹1,800 target
In short
Motilal Oswal began covering Molbio Diagnostics with a Buy rating and a ₹1,800 target price. It said that target suggests about 21% upside.
The broker likes the company’s Truenat platform, which it says has 12,500+ devices in 90+ countries and 43 tests for 30 diseases. The report does not say when the note was published.
What the reporting says
Motilal Oswal initiated coverage on Molbio Diagnostics with a Buy rating and a ₹1,800 target price, implying 21% upside. The brokerage cited growth potential from decentralised molecular diagnostics and Molbio’s Truenat platform, which it said has more than 12,500 devices across 90+ countries and 43 assays for 30 diseases. The reporting does not say when the coverage note was issued or whether the target has changed since.
Why it matters
Motilal Oswal initiated coverage on Molbio Diagnostics with a Buy recommendation and a ₹1,800 target, implying 21% upside. The note highlighted decentralised molecular diagnostics and the company’s Truenat platform, said to have 12,500+ devices across 90+ countries and 43 assays for 30 diseases. The reporting does not include management commentary or confirm any immediate trading reaction.